Skip to main content
Top
Published in: Clinical and Experimental Nephrology 1/2011

01-02-2011 | Original Article

Aldosterone-induced kidney injury is mediated by NFκB activation

Authors: Seiichi Fukuda, Chihiro Horimai, Kaori Harada, Toshifumi Wakamatsu, Hiroshi Fukasawa, Susumu Muto, Akiko Itai, Matsuhiko Hayashi

Published in: Clinical and Experimental Nephrology | Issue 1/2011

Login to get access

Abstract

Background

Aldosterone induces inflammation and fibrosis in the kidney, while nuclear factor κB (NFκB) plays key roles in inflammation mediated by various cytokines. Here, we determined the roles of NFκB activation in aldosterone-induced kidney injury.

Methods

We used unilaterally nephrectomized rats with or without continuous aldosterone infusion and 0.9% saline as drinking water for 3 weeks. IMD-1041, an IKKβ inhibitor, and spironolactone were orally administered to inhibit NFκB and mineralocorticoid receptor, respectively.

Results

The aldosterone-infused rats exhibited severe kidney injury, hypertension, and increased expression of pro-inflammatory and fibrotic proteins, osteopontin, fibrinogen, collagen type I, and PAI-1. Western blotting confirmed NFκB activation by aldosterone by the increased amount of p65 in the nuclear fraction of the kidney, and oral IMD-1041 prevented the kidney injury and lessened the increase in pro-inflammatory and fibrotic proteins without significant changes in blood pressures. In addition, changes in angiotensin-converting enzyme 2 (ACE2), which has been found to act as a protective factor in various kidney injury models, were examined. Immunofluorescence studies revealed the presence of ACE2 in the brush-border membrane of the proximal convoluted tubules and markedly blunted ACE2 staining in aldosterone-infused rats. The decrease in amount of ACE2 protein was confirmed by Western blotting, and IMD-1041 also prevented the decrease in ACE2. The administration of spironolactone also abolished the effects of aldosterone.

Conclusion

Our results suggest that aldosterone induces kidney injury via activation of NFκB and mineralocorticoid receptor, and that decreased ACE2 expression may play an important role in aldosterone-induced kidney injury.
Literature
1.
go back to reference Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010;6:261–73.CrossRefPubMed Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010;6:261–73.CrossRefPubMed
2.
go back to reference De Seigneux S, Leroy V, Ghzili H, Rousselot M, Nielsen S, Rossier BC, et al. NFκB inhibits sodium transport via down-regulation of SGK1 in renal collecting duct principal cells. J Biol Chem. 2008;283:25671–81.CrossRefPubMed De Seigneux S, Leroy V, Ghzili H, Rousselot M, Nielsen S, Rossier BC, et al. NFκB inhibits sodium transport via down-regulation of SGK1 in renal collecting duct principal cells. J Biol Chem. 2008;283:25671–81.CrossRefPubMed
3.
go back to reference Leroy V, De Seigneux S, Agassiz V, Hasler U, Rafestin-Oblin ME, Vinciguerra M, et al. Aldosterone activates NFκB in the collecting duct. J Am Soc Nephrol. 2009;20:131–44.CrossRefPubMed Leroy V, De Seigneux S, Agassiz V, Hasler U, Rafestin-Oblin ME, Vinciguerra M, et al. Aldosterone activates NFκB in the collecting duct. J Am Soc Nephrol. 2009;20:131–44.CrossRefPubMed
4.
go back to reference Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-κB activation in angiotensin-II induced cardiac injury. Hypertension. 2001;37:787–93.PubMed Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-κB activation in angiotensin-II induced cardiac injury. Hypertension. 2001;37:787–93.PubMed
5.
go back to reference Terada Y, Kuwana H, Kobayashi T, Okado T, Suzuki N, Yoshimoto T, et al. Aldosterone-stimulated SGK1 activity mediates profibrotic signaling in the mesangium. J Am Soc Nephrol. 2008;19:298–309.CrossRefPubMed Terada Y, Kuwana H, Kobayashi T, Okado T, Suzuki N, Yoshimoto T, et al. Aldosterone-stimulated SGK1 activity mediates profibrotic signaling in the mesangium. J Am Soc Nephrol. 2008;19:298–309.CrossRefPubMed
6.
go back to reference Irita J, Okura T, Kurata M, Miyoshi K, Fukuoka T, Higaki J. Osteopontin in rat renal fibroblasts: functional properties and transcriptional regulation by aldosterone. Hypertension. 2008;51:507–13.CrossRefPubMed Irita J, Okura T, Kurata M, Miyoshi K, Fukuoka T, Higaki J. Osteopontin in rat renal fibroblasts: functional properties and transcriptional regulation by aldosterone. Hypertension. 2008;51:507–13.CrossRefPubMed
7.
go back to reference Bergmann A, Eulenberg C, Wellner M, Rolle S, Luft F, Kettritz R. Aldosterone abrogates nuclear factor κB-mediated tumor necrosis factor α production in human neutrophils via the mineralocorticoid receptor. Hypertension. 2010;55:370–9.CrossRefPubMed Bergmann A, Eulenberg C, Wellner M, Rolle S, Luft F, Kettritz R. Aldosterone abrogates nuclear factor κB-mediated tumor necrosis factor α production in human neutrophils via the mineralocorticoid receptor. Hypertension. 2010;55:370–9.CrossRefPubMed
8.
go back to reference Onai Y, Suzuki J, Maejima Y, Haraguchi G, Muto S, Itai A, et al. Inhibition of NF-κB improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. Am J Physiol Heart Circ Physiol. 2007;292:H530–8.CrossRefPubMed Onai Y, Suzuki J, Maejima Y, Haraguchi G, Muto S, Itai A, et al. Inhibition of NF-κB improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. Am J Physiol Heart Circ Physiol. 2007;292:H530–8.CrossRefPubMed
9.
go back to reference Onai Y, Suzuki J, Kakuta T, Maejima Y, Haraguchi G, Fukasawa H, et al. Inhibition of IκB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc Res. 2004;63:51–9.CrossRefPubMed Onai Y, Suzuki J, Kakuta T, Maejima Y, Haraguchi G, Fukasawa H, et al. Inhibition of IκB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc Res. 2004;63:51–9.CrossRefPubMed
10.
go back to reference Takase O, Hirahashi J, Takayanagi A, Chikaraishi A, Marumo T, Ozawa Y, et al. Gene transfer of truncated IκBα prevents tubulointerstitial injury. Kidney Int. 2003;63:501–13.CrossRefPubMed Takase O, Hirahashi J, Takayanagi A, Chikaraishi A, Marumo T, Ozawa Y, et al. Gene transfer of truncated IκBα prevents tubulointerstitial injury. Kidney Int. 2003;63:501–13.CrossRefPubMed
11.
go back to reference Takase O, Marumo T, Imai N, Hirahashi J, Takayanagi A, Hishikawa K, et al. NF-κB-dependent increase in intrarenal angiotensin II induced by proteinuria. Kidney Int. 2005;68:464–73.CrossRefPubMed Takase O, Marumo T, Imai N, Hirahashi J, Takayanagi A, Hishikawa K, et al. NF-κB-dependent increase in intrarenal angiotensin II induced by proteinuria. Kidney Int. 2005;68:464–73.CrossRefPubMed
12.
go back to reference Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63:1791–800.CrossRefPubMed Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63:1791–800.CrossRefPubMed
13.
go back to reference Smale ST. Selective transcription in response to an inflammatory stimulus. Cell. 2010;140:833–44.CrossRefPubMed Smale ST. Selective transcription in response to an inflammatory stimulus. Cell. 2010;140:833–44.CrossRefPubMed
14.
go back to reference Lee FT, Cao Z, Long DM. Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol. 2004;15:2139–51.CrossRefPubMed Lee FT, Cao Z, Long DM. Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol. 2004;15:2139–51.CrossRefPubMed
15.
go back to reference Li L, Emmett N, Mann D, Zhao X. Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. Exp Biol Med. 2010;235:383–91.CrossRef Li L, Emmett N, Mann D, Zhao X. Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. Exp Biol Med. 2010;235:383–91.CrossRef
16.
go back to reference Mezzano SA, Barría M, Droguett MA, Burgos ME, Ardiles LG, Flores C, et al. Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease. Kidney Int. 2001;60:1366–77.CrossRefPubMed Mezzano SA, Barría M, Droguett MA, Burgos ME, Ardiles LG, Flores C, et al. Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease. Kidney Int. 2001;60:1366–77.CrossRefPubMed
17.
go back to reference Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int. 2006;69:1064–72.CrossRefPubMed Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int. 2006;69:1064–72.CrossRefPubMed
18.
go back to reference Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension. 2003;41:392–7.CrossRefPubMed Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension. 2003;41:392–7.CrossRefPubMed
19.
go back to reference Tikellis C, Cooper ME, Bialkowski K, Johnston CI, Burns WC, Lew RA, et al. Developmental expression of ACE2 in the SHR kidney: a role in hypertension? Kidney Int. 2006;70:34–41.CrossRefPubMed Tikellis C, Cooper ME, Bialkowski K, Johnston CI, Burns WC, Lew RA, et al. Developmental expression of ACE2 in the SHR kidney: a role in hypertension? Kidney Int. 2006;70:34–41.CrossRefPubMed
20.
go back to reference Joyner J, Neves LA, Granger JP, Alexander BT, Merrill DC, Chappell MC. Temporal–spatial expression of ANG-(1–7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats. Am J Physiol Regul Integr Comp Physiol. 2007;293:R169–77.PubMed Joyner J, Neves LA, Granger JP, Alexander BT, Merrill DC, Chappell MC. Temporal–spatial expression of ANG-(1–7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats. Am J Physiol Regul Integr Comp Physiol. 2007;293:R169–77.PubMed
21.
go back to reference Moon JY, Jeong K-H, Lee S-H, Lee TW, Ihm CG, Lim SJ. Renal ACE and ACE2 expression in early diabetic rats. Nephron Exp Nephrol. 2008;110:e8–16.CrossRefPubMed Moon JY, Jeong K-H, Lee S-H, Lee TW, Ihm CG, Lim SJ. Renal ACE and ACE2 expression in early diabetic rats. Nephron Exp Nephrol. 2008;110:e8–16.CrossRefPubMed
22.
go back to reference Velkoska E, Dean RG, Burchill L, Levidiotis V, Burrell LM. Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition. Clin Sci. 2010;118:269–79.CrossRefPubMed Velkoska E, Dean RG, Burchill L, Levidiotis V, Burrell LM. Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition. Clin Sci. 2010;118:269–79.CrossRefPubMed
23.
go back to reference Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus AD, et al. The emerging role of ACE2 in physiology and disease. J Pathol. 2007;212:1–11.CrossRefPubMed Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus AD, et al. The emerging role of ACE2 in physiology and disease. J Pathol. 2007;212:1–11.CrossRefPubMed
24.
go back to reference Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int. 2008;74:1610–8.CrossRefPubMed Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int. 2008;74:1610–8.CrossRefPubMed
25.
go back to reference Yamamuro M, Yoshimura M, Nakayama M, Abe K, Sumida H, Sugiyama S, et al. Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes. Circ J. 2008;72:1346–50.CrossRefPubMed Yamamuro M, Yoshimura M, Nakayama M, Abe K, Sumida H, Sugiyama S, et al. Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes. Circ J. 2008;72:1346–50.CrossRefPubMed
26.
go back to reference Rickard AJ, Young MJ. Corticosteroid receptors, macrophages and cardiovascular disease. J Mol Endocrinol. 2009;42:449–59.CrossRefPubMed Rickard AJ, Young MJ. Corticosteroid receptors, macrophages and cardiovascular disease. J Mol Endocrinol. 2009;42:449–59.CrossRefPubMed
27.
go back to reference Gilbert KC, Brown NJ. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes. 2010;17:199–204.CrossRefPubMed Gilbert KC, Brown NJ. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes. 2010;17:199–204.CrossRefPubMed
Metadata
Title
Aldosterone-induced kidney injury is mediated by NFκB activation
Authors
Seiichi Fukuda
Chihiro Horimai
Kaori Harada
Toshifumi Wakamatsu
Hiroshi Fukasawa
Susumu Muto
Akiko Itai
Matsuhiko Hayashi
Publication date
01-02-2011
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 1/2011
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-010-0373-1

Other articles of this Issue 1/2011

Clinical and Experimental Nephrology 1/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.